Lokhandwala Shehnaz, Waghela Suryakant D, Bray Jocelyn, Martin Cameron L, Sangewar Neha, Charendoff Chloe, Shetti Rashmi, Ashley Clay, Chen Chang-Hsin, Berghman Luc R, Mwangi Duncan, Dominowski Paul J, Foss Dennis L, Rai Sharath, Vora Shaunak, Gabbert Lindsay, Burrage Thomas G, Brake David, Neilan John, Mwangi Waithaka
Department of Veterinary Pathobiology, Texas A&M University, College Station, Texas, USA
Department of Veterinary Pathobiology, Texas A&M University, College Station, Texas, USA.
Clin Vaccine Immunol. 2016 Nov 4;23(11):888-900. doi: 10.1128/CVI.00395-16. Print 2016 Nov.
The African swine fever virus (ASFV) causes a fatal hemorrhagic disease in domestic swine, and at present no treatment or vaccine is available. Natural and gene-deleted, live attenuated strains protect against closely related virulent strains; however, they are yet to be deployed and evaluated in the field to rule out chronic persistence and a potential for reversion to virulence. Previous studies suggest that antibodies play a role in protection, but induction of cytotoxic T lymphocytes (CTLs) could be the key to complete protection. Hence, generation of an efficacious subunit vaccine depends on identification of CTL targets along with a suitable delivery method that will elicit effector CTLs capable of eliminating ASFV-infected host cells and confer long-term protection. To this end, we evaluated the safety and immunogenicity of an adenovirus-vectored ASFV (Ad-ASFV) multiantigen cocktail formulated in two different adjuvants and at two immunizing doses in swine. Immunization with the cocktail rapidly induced unprecedented ASFV antigen-specific antibody and cellular immune responses against all of the antigens. The robust antibody responses underwent rapid isotype switching within 1 week postpriming, steadily increased over a 2-month period, and underwent rapid recall upon boost. Importantly, the primed antibodies strongly recognized the parental ASFV (Georgia 2007/1) by indirect fluorescence antibody (IFA) assay and Western blotting. Significant antigen-specific gamma interferon-positive (IFN-γ) responses were detected postpriming and postboosting. Furthermore, this study is the first to demonstrate induction of ASFV antigen-specific CTL responses in commercial swine using Ad-ASFV multiantigens. The relevance of the induced immune responses in regard to protection needs to be evaluated in a challenge study.
非洲猪瘟病毒(ASFV)可在家猪中引发致命的出血性疾病,目前尚无治疗方法或疫苗。天然减毒株和基因缺失活疫苗可抵御密切相关的强毒株;然而,它们尚未在野外进行部署和评估,以排除慢性持续性感染和毒力回复的可能性。先前的研究表明,抗体在保护中发挥作用,但诱导细胞毒性T淋巴细胞(CTL)可能是实现完全保护的关键。因此,研发有效的亚单位疫苗取决于识别CTL靶点以及合适的递送方法,以引发能够消除ASFV感染宿主细胞并提供长期保护的效应CTL。为此,我们评估了在两种不同佐剂中配制并以两种免疫剂量免疫猪的腺病毒载体ASFV(Ad-ASFV)多抗原混合物的安全性和免疫原性。用该混合物免疫可迅速诱导出前所未有的针对所有抗原的ASFV抗原特异性抗体和细胞免疫反应。强烈的抗体反应在初次免疫后1周内迅速发生同种型转换,在2个月内稳步增加,并在加强免疫后迅速回升。重要的是,通过间接荧光抗体(IFA)检测和蛋白质印迹法,初次免疫产生的抗体能强烈识别亲本ASFV(格鲁吉亚2007/1)。在初次免疫和加强免疫后均检测到显著的抗原特异性γ干扰素阳性(IFN-γ)反应。此外,本研究首次证明使用Ad-ASFV多抗原在商品猪中诱导出ASFV抗原特异性CTL反应。诱导的免疫反应在保护方面的相关性需要在攻毒试验中进行评估。